NCT01423721

Brief Summary

The objective of the current study is to investigate relative bioavailability of bromhexine hydrochloride given as granules and syrup

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P50-P75 for phase_1 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

August 25, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 26, 2011

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
Last Updated

November 1, 2013

Status Verified

October 1, 2013

Enrollment Period

2 months

First QC Date

August 25, 2011

Last Update Submit

October 31, 2013

Conditions

Outcome Measures

Primary Outcomes (2)

  • AUC0-tz (area under the plasma concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)

    48 h

  • Cmax (maximum measured concentration of the analyte in plasma)

    48 h

Secondary Outcomes (1)

  • AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to infinity)

    48 h

Study Arms (2)

Bromihexine hydrochloride granules

EXPERIMENTAL

16 mg granules

Drug: Bromihexine hydrochloride granules

Bromihexine hydrochloride syrup

EXPERIMENTAL

16 mg syrup

Drug: Bromihexine hydrochloride syrup

Interventions

syrup

Bromihexine hydrochloride syrup

granules

Bromihexine hydrochloride granules

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • \- Healthy male and female volunteers

You may not qualify if:

  • \- Any relevant deviation from healthy conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

65.129.1 Boehringer Ingelheim Investigational Site

Biberach, Germany

Location

Study Officials

  • Boehringer Ingelheim

    Boehringer Ingelheim

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 25, 2011

First Posted

August 26, 2011

Study Start

August 1, 2011

Primary Completion

October 1, 2011

Last Updated

November 1, 2013

Record last verified: 2013-10

Locations